XML 65 R19.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Investments accounted for using the equity method | 12 Months Ended
--- | ---
Dec. 31, 2023
Interests In Other Entities [Abstract] |
Investments accounted for using the equity method | Investments accounted for using the equity method Investments accounted for using the equity method comprise associates and joint ventures (see Note B.1.), and are set forth below.
(€ million) | % interest | 2023 | 2022 | 2021
EUROAPI(a) | 29.8 |  | 162 |  | 392 |  | — |
Infraserv GmbH & Co. Höchst KG(b) | 31.2 |  | 90 |  | 97 |  | 80 |
MSP Vaccine Company(c) | 50.0 |  | 96 |  | 104 |  | 88 |
Other investments | — |  | 76 |  | 84 |  | 82 |
Total |  | 424 |  | 677 |  | 250 |
(a) Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS 28 (see Note D.2.). As of December 31, 2023, an impairment loss of €231 million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March 2023. The amount of the loss was determined on the basis of the share price as of December 31, 2023 (€5.73). (b) Joint venture. (c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV. The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material):
| 2023 | 2022 | 2021 |
(€ million) | Joint ventures | Associates | Joint ventures | Associates | Joint ventures | Associates |
Share of profit/(loss) from investments accounted for using the equity method(a) | 101 |  | (216) |  | 74 |  | (6) |  | 26 |  | 13 |  |
Share of other comprehensive income from investments accounted for using the equity method | (7) |  | 8 |  | (2) |  | (3) |  | (6) |  | — |  |
Total | 94 |  | (208) |  | 72 |  | (9) |  | 20 |  | 13 |  |
(a) An impairment loss of €231 million was recognized on the equity-accounted interest in EUROAPI as of December 31, 2023, to reflect the fall in the share price since March 2023. The amount of the loss was determined on the basis of the quoted market price as of December 31, 2023 (€5.73). The financial statements include arm’s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:
(€ million) | 2023 |  |  | 2022 | (a) | 2021 |
Sales | 157 |  |  |  | 131 |  |  | 70 |  |
Royalties and other income | 63 |  |  |  | 81 |  |  | 66 |  |
Accounts receivable and other receivables(b) | 249 |  |  |  | 330 |  |  | 269 |  |
Purchases and other expenses (including research expenses) | 642 |  |  |  | 477 |  |  | 178 |  |
Accounts payable and other payables | 71 |  |  |  | 132 |  |  | 28 |  |
(a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.2.). (b) Includes loans to joint ventures and associates. There were no funding commitments to associates and joint ventures as of December 31, 2023, December 31, 2022 or December 31, 2021. For off balance sheet commitments of an operational nature involving joint ventures, see Note D.21.1.

X
- Definition The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | sny_InterestsInOtherEntitiesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration